Xvivo Perfusion AB (publ)

OM:XVIVO Stock Report

Market Cap: SEK 5.9b

Xvivo Perfusion Valuation

Is XVIVO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XVIVO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XVIVO (SEK187.9) is trading below our estimate of fair value (SEK940.95)

Significantly Below Fair Value: XVIVO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XVIVO?

Key metric: As XVIVO is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XVIVO. This is calculated by dividing XVIVO's market cap by their current revenue.
What is XVIVO's PS Ratio?
PS Ratio7.3x
SalesSEK 813.59m
Market CapSEK 5.92b

Price to Sales Ratio vs Peers

How does XVIVO's PS Ratio compare to its peers?

The above table shows the PS ratio for XVIVO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.9x
VIMIAN Vimian Group
3.5x8.91%SEK 15.8b
OSSD OssDsign
7.2x24.62%SEK 1.3b
ASKER Asker Healthcare Group
2x11.28%SEK 32.4b
BACTI B Bactiguard Holding
3x12.30%SEK 646.6m
XVIVO Xvivo Perfusion
7.3x22.72%SEK 5.9b

Price-To-Sales vs Peers: XVIVO is expensive based on its Price-To-Sales Ratio (7.3x) compared to the peer average (3.9x).

Price to Sales Ratio vs Industry

How does XVIVO's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 CompaniesPrice / SalesEstimated GrowthMarket Cap
ARJO B Arjo
0.8x2.66%US$920.31m
ADDV A ADDvise Group
0.6x3.64%US$98.83m
CARE Careium
0.7x7.78%US$60.89m
BOUL Boule Diagnostics
0.4x4.03%US$22.54m
XVIVO 7.3xIndustry Avg. 4.2xNo. of Companies12PS048121620+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XVIVO is expensive based on its Price-To-Sales Ratio (7.3x) compared to the Swedish Medical Equipment industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is XVIVO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XVIVO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.3x
Fair PS Ratio6.7x

Price-To-Sales vs Fair Ratio: XVIVO is expensive based on its Price-To-Sales Ratio (7.3x) compared to the estimated Fair Price-To-Sales Ratio (6.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XVIVO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 187.90
SEK 319.60
+70.09%
21.22%SEK 408.00SEK 225.00n/a5
Dec ’26SEK 178.10
SEK 319.60
+79.45%
21.22%SEK 408.00SEK 225.00n/a5
Nov ’26SEK 189.50
SEK 319.60
+68.65%
21.22%SEK 408.00SEK 225.00n/a5
Oct ’26SEK 169.60
SEK 331.60
+95.52%
23.68%SEK 425.00SEK 215.00n/a5
Sep ’26SEK 177.00
SEK 345.60
+95.25%
21.47%SEK 425.00SEK 215.00n/a5
Aug ’26SEK 197.40
SEK 346.00
+75.28%
21.54%SEK 425.00SEK 215.00n/a5
Jul ’26SEK 287.20
SEK 446.00
+55.29%
15.13%SEK 520.00SEK 320.00n/a6
Jun ’26SEK 306.40
SEK 448.50
+46.38%
14.02%SEK 520.00SEK 335.00n/a6
May ’26SEK 319.20
SEK 448.50
+40.51%
14.02%SEK 520.00SEK 335.00n/a6
Apr ’26SEK 291.50
SEK 476.17
+63.35%
17.05%SEK 567.00SEK 325.00n/a6
Mar ’26SEK 444.00
SEK 518.67
+16.82%
8.84%SEK 567.00SEK 460.00n/a6
Feb ’26SEK 466.00
SEK 522.00
+12.02%
8.06%SEK 567.00SEK 480.00n/a6
Jan ’26SEK 489.00
SEK 538.17
+10.05%
7.79%SEK 584.00SEK 480.00n/a6
Dec ’25SEK 480.00
SEK 538.17
+12.12%
7.79%SEK 584.00SEK 480.00SEK 178.106
Nov ’25SEK 448.00
SEK 545.67
+21.80%
6.26%SEK 584.00SEK 480.00SEK 189.506
Oct ’25SEK 503.00
SEK 549.00
+9.15%
6.57%SEK 584.00SEK 480.00SEK 169.606
Sep ’25SEK 533.00
SEK 549.00
+3.00%
6.57%SEK 584.00SEK 480.00SEK 177.006
Aug ’25SEK 506.00
SEK 549.00
+8.50%
6.57%SEK 584.00SEK 480.00SEK 197.406
Jul ’25SEK 418.00
SEK 440.00
+5.26%
13.89%SEK 520.00SEK 340.00SEK 287.206
Jun ’25SEK 440.00
SEK 408.00
-7.27%
12.02%SEK 468.00SEK 340.00SEK 306.406
May ’25SEK 379.00
SEK 408.00
+7.65%
12.02%SEK 468.00SEK 340.00SEK 319.206
Apr ’25SEK 275.00
SEK 382.60
+39.13%
9.01%SEK 425.00SEK 340.00SEK 291.505
Mar ’25SEK 280.50
SEK 382.60
+36.40%
9.01%SEK 425.00SEK 340.00SEK 444.005
Feb ’25SEK 284.50
SEK 389.60
+36.94%
7.81%SEK 425.00SEK 340.00SEK 466.005
Jan ’25SEK 329.50
SEK 377.00
+14.42%
16.34%SEK 450.00SEK 280.00SEK 489.005
Dec ’24SEK 273.00
SEK 363.75
+33.24%
17.10%SEK 450.00SEK 280.00SEK 480.004
SEK 319.6
Fair Value
41.2% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/21 14:14
End of Day Share Price 2025/12/19 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Erik CasselDanske Bank
Daniel AlbinDanske Bank